Hostname: page-component-89b8bd64d-rbxfs Total loading time: 0 Render date: 2026-05-13T06:32:24.763Z Has data issue: false hasContentIssue false

Helminth parasite proteomics: from experimental models to human infections

Published online by Cambridge University Press:  28 March 2012

FRANCISCA MUTAPI*
Affiliation:
Centre for Immunity Infection and Evolution, Institute of Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, West Mains Rd, Edinburgh, EH9 3JT, UK
*
*Corresponding Author: Dr Francisca Mutapi, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Ashworth Laboratories, King's Buildings, West Mains Rd, Edinburgh, EH9 3JT. Tel: +44 131 650 8662. Fax: +44 131 650 5450. E-mail: f.mutapi@ed.ac.uk
Rights & Permissions [Opens in a new window]

Summary

Schistosomiasis is a major human helminth infection endemic in developing countries. Urogenital schistosomiasis, caused by S. haematobium, is the most prevalent human schistosome disease in sub-Saharan Africa. Currently control of schistosome infection is by treatment of infected people with the anthelmintic drug praziquantel, but there are calls for continued efforts to develop a vaccine against the parasites. In order for successful vaccine development, it is necessary to understand the biology and molecular characteristics of the parasite. Ultimately, there is need to understand the nature and dynamics of the relationship between the parasite and the natural host. Thus, my studies have focused on molecular characterization of different parasite stages and integrating this information with quantitative approaches to investigate the nature and development of protective immunity against schistosomes in humans. Proteomics has proved a powerful tool in these studies allowing the proteins expressed by the parasite to be characterized at a molecular and immunological level. In this review, the application of proteomic approaches to understanding the human-schistosome relationship as well as testing specific hypotheses on the nature and development of schistosome-specific immune responses is discussed. The contribution of these approaches to informing schistosome vaccine development is highlighted.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2012. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use.
Figure 0

Fig. 1. A summary of the difference gel electrophoresis (DiGE) used to compare abundance of proteins between difference proteomes. The proteins from each proteome are labelled with fluorescent dyes (for example Cy3, Cy5, Cy2) prior to two-dimensional electrophoresis. After the gel electrophoresis, the gel is scanned with the excitation wavelength of each dye one after the other. Quantitative analysis is then conducted through differential in gel analysis (DIA) with image analysis software such as DeCyder from GE Healthcare.

Figure 1

Fig. 2. Differential in gel analysis (DIA) images for the comparison between schistosomes and the echinostsome parasites showing the different abundances of different proteins and the corresponding histogram comparing the abundance of each protein spot on the gel as well as the overall % similarity in the proteomes.A) Comparing S. haematobium with S. bovis. Green spots=higher expression in S. haematobium; Red spots=higher expression in S. bovis; Blue spots=expression levels similar in both species.B) Comparing E. caproni with S. haematobium. Green spots=higher expression in S. haematobium; Red spots=higher expression in E. caproni; Blue spots=expression levels similar in both species.C) Comparing E. caproni with S. bovis. Green spots=higher expression in E. caproni; Red spots=higher expression in S. bovis; Blue spots=expression levels similar in both species. Fig. adapted from Higon et al. 2011.

Figure 2

Table 1. Characterization of natural and praziquantel-induced schistosome antigen recognition profiles by Zimbabwean populations exposed to S. haematobium infection. World Health Organization-listed schistosome vaccine candidates are highlighted in bold. Un-shaded cells denote no recognition (1st quartile range), yellow denote low intensity of recognition (2nd interquartile, orange denote medium intensity (3rd quartile) and red denote strong intensity (4th quartile) for both. Changes in total IgG recognition profiles with age and infection level and Ag recognition by different Ab subclasses. For the Ag recognition profile by age and infection intensity the population was divided into 9 groups as follows: group 1–3 are all aged 5–10 years and have zero (Group 1), mild (1–49 eggs/10 ml urine) (Group 2) and heavy (50+eggs/10 ml urine) (Group 3) infection levels, respectively, groups 4–6 are all aged 11–13 years and have 0 (Group 4), mild (Group 5) and heavy (Group 6) infection levels, respectively and finally groups 7–9 are all aged 14–18 years and have 0 (Group 7), mild (Group 8) and heavy (Group 9) infection levels. The middle column (Rx) represents antigens recognised before and after treatment (yellow) and those recognised only after anthelmintic treatment (red). Table adapted from (Mutapi et al. 2008, 2011).